A Randomized, Open Label, Parallel Design, Single Continuous Intravenous Infusion Study of BMS-986231 to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Formulations in Healthy Participants
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Cimlanod (Primary)
- Indications Decompensated heart failure; Heart failure
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 27 Sep 2019 Status changed from active, no longer recruiting to completed.
- 05 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Mar 2019 New trial record